Literature DB >> 2158900

Converting enzyme inhibition and vascular prostacyclin synthesis: effect of kinin receptor antagonism.

G Hoffmann1, R Pietsch, B O Göbel, B Weisser, G Bönner, H Vetter, R Düsing.   

Abstract

The effects of angiotensin I-converting enzyme (ACE) inhibitors and bradykinin (BK) on prostacyclin (PGI2) production in isolated arterial tissue were investigated. Rings of rat abdominal aorta were incubated in Krebs-Ringer bicarbonate buffer and PGI2 generation was assessed by the determination of its stable hydrolysis product; 6-keto-PGF1 alpha. The addition of both ACE inhibitors, captopril and lisinopril, and bradykinin resulted in dose-dependent stimulation of PGI2 biosynthesis when the individual substance was added into the incubation buffer at final concentrations between 10(-8) and 10(-5) M. The bradykinin-induced stimulation of PGI2 synthesis was dose dependently inhibited by the BK receptor antagonist, D-Arg[Hyp3, Thi5,8, D-Phe7]BK. The captopril- and lisinopril-induced stimulation of vascular 6-keto-PGF1 alpha production was also significantly decreased when the BK antagonist was added to the incubation medium together with the ACE inhibitors. Our results show that both captopril and lisinopril stimulate PGI2 synthesis in arterial tissue and that this effect may be secondary to changes in the activity of the kinin system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158900     DOI: 10.1016/0014-2999(90)94795-y

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

2.  Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors.

Authors:  Hiroshi Yamanari; Kazufumi Nakamura; Mikio Kakishita; Tohru Ohe
Journal:  Clin Cardiol       Date:  2004-09       Impact factor: 2.882

3.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

Authors:  F J Hock; K Wirth; U Albus; W Linz; H J Gerhards; G Wiemer; S Henke; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.